Protocol Ledger

NCT03758417 · Phase II · TERMINATED

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Interventional Phase II clinical trial protocol NCT03758417 sponsored by Nanjing Legend Biotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-23 Enrollment: 123 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03758417
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)123 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03758417
Protocol FieldVerified Registry Value
NCT IdentifierNCT03758417
Consolidated Lead SponsorNanjing Legend Biotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment123 participants (ACTUAL)
Registered Start Date2019-01-23
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03758417
Hospital Research SiteLocationSite Profile
Peking University Third HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Medical University Union HospitalFuzhou, ChinaOpen Hospital Dossier ->
Nanjing Drum Tower HospitalNanjing, ChinaOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI